Companies › Atridia
4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Immunology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HRS-5041 | – | Phase 1 | Metastatic Castration Resistant Prostate Cancer | Dec 2026 |
| HRS-6209 | – | Phase 1 | Breast Cancer | Apr 2027 |
| SHR-1139 | – | Phase 1 | Psoriasis; Pyoderma Gangrenosum | – |
| SHR-2173 | – | Phase 1 | Immunology | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07390747 | SHR-2173 | Phase 1 | Immunology | Other | May 2026 |
| NCT07078695 | SHR-1139 | Phase 1 | Psoriasis | Immunology | Sep 2026 |
| NCT06830850 | HRS-5041 | Phase 1 | Metastatic Castration Resistant Prostate Cancer | Oncology | Dec 2026 |
| NCT07358377 | HRS-6209 | Phase 1 | Breast Cancer | Oncology | Apr 2027 |
| NCT07337564 | SHR-1139 | Phase 2 | Pyoderma Gangrenosum | Immunology | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.